论文部分内容阅读
单抗2C10为一株抗结直肠癌抗体,与卵巢癌和胃癌有交叉反应。以放射性核素111-In标记,裸鼠实验显示良好的肿瘤定位效果。临床应用共检查病人15例。其中结直肠癌11例,卵巢癌2例,胃癌2例。肿瘤类型以腺癌为主。其中10例经手术、病理证实,肿瘤最大体积为10×8×7cm(卵巢癌):最小体积为3×3×2cm(胃癌)和3×3×5cm(直肠癌)。另外5例经纤维内窥镜、B超及X光证实。病人检查前一般行肝、肾功能及常规检查和血清CEA水平测定。注射前作过敏皮试并予抗过敏药防止过敏反应。 药检合格之2C10无菌条件下标记111-In,以2～3mCi/1mg的剂量加入100ml生理
The monoclonal antibody 2C10 is an anti-CRC antibody with cross-reactivity to ovarian cancer and gastric cancer. Labeled with radionuclide 111-In, nude mice experiments showed good tumor localization. Clinical application A total of 15 patients were examined. There were 11 cases of colorectal cancer, 2 cases of ovarian cancer, and 2 cases of gastric cancer. The main type of cancer is adenocarcinoma. Among them, 10 cases were confirmed by surgery and pathology. The maximum tumor volume was 10 x 8 x 7 cm (ovarian cancer): the minimum volume was 3 x 3 x 2 cm (gastric cancer) and 3 x 3 x 5 cm (rectal cancer). The other 5 cases were confirmed by fiberoptic endoscopy, B-ultrasonography, and X-ray. Before the examination, liver and kidney function and routine examinations and serum CEA levels were generally measured. Allergic skin test before injection and anti-allergic drugs to prevent allergic reactions. 2C10 labeled with drug test is marked with 111-In under aseptic conditions, and 100ml physiological is added at a dose of 2～3mCi/1mg.